Kamada (TASE:KMDA), a biopharmaceutical company which develops, manufactures and markets specialty life-saving therapeutics, announces that the company will soon start phase II clinical trials with the inhaled version of its Alpha-1 Antitrypsin (AAT) product to treat Bronchiectasis, a lung disease that results in the distortion of one or more of the conducting bronchi or airways, most often secondary to an infectious process.
(more...)